Individuals received either intravenous administration of 0.5 mg/kg enoxaparin ) without anticoagulation monitoring/dose adjusted or standard UFH prior to primary Percutaneous Coronary Intervention, a procedure also known as angioplasty and stenting. With regard to major bleeding risk, the primary security endpoint, no difference was observed in the two treatment groups . The same observation was reported with minimal bleeding risk .. ATOLL study favors enoxaparin over UFH for major Percutaneous Coronary Intervention – Composite Principal Endpoint: Risk Reduction of 17 percent in Loss of life, Complication of Myocardial Infraction, Procedure Failure or Main Bleeding – Main Secondary Composite Efficacy Endpoint: 40 percent Reduced amount of Loss of life, Recurrent Acute Coronary Syndrome or Re-Intervention The international ATOLL study sponsored by the Assistance Publique – Hopitaux de Paris demonstrated that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failing or major bleeding by 17 percent in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation.In 2006, IAVI released a Stage II trial in Uganda and Zambia, section of a multi-site study that also included three sites in South Africa. The South Africa, Uganda and Zambia trial sites are completely enrolled with data expected later this year now. Two of the most advanced trials underway in 2007 are from Sanofi-Pasteur and Merck & Co., Inc. Data from Merck’s ongoing Phase IIb test-of-concept trial using its adeno-5 vector vaccine candidate is expected in 2008-2009 and will provide preliminary details on the efficacy of the type of vaccine applicant.